Quince’s highly differentiated autologous intracellular drug encapsulation (AIDE) technology platform is designed to enable the delivery of a therapeutic using a patient’s own blood.
By leveraging a patient’s own biology to deliver a therapeutic encapsulated in autologous red blood cells, our proprietary AIDE technology is believed to fundamentally alter a drug’s pharmacokinetics to allow for chronic administration for the potential treatment of rare diseases. This unique autologous delivery approach holds the potential to provide life-changing innovative therapeutics to address underserved rare disease patients with high unmet medical need.
Quince’s Phase 3 lead asset, EryDex, utilizes this AIDE technology platform and is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using a patient’s own red blood cells to deliver the sustained therapeutic over a once monthly treatment period. Designed for the potential treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T), we plan to advance a single global Phase 3 clinical trial entitled NEAT (#IDEAT-04-2022 – Neurologic Effects of EryDex on Subjects with A–T) to evaluate the neurological effects of EryDex on patients with A-T. Enrollment for the Phase 3 NEAT trial is anticipated to begin in the second quarter of 2024.